FDA Crackdown on Telehealth and GLP-1 Drug Marketing Sparks Industry Shift

The FDA is intensifying oversight on telehealth marketing practices for GLP-1 drugs, scrutinizing who prescribes these medications. This move targets unapproved weight loss drugs, impacting providers and patients relying on telehealth. Future regulatory actions may reshape the telehealth landscape and influence drug approval processes.